UBS has given DocMorris a "Sell" rating with a price target of 25 francs.
According to analyst Olivier Calvet, recent evaluation shows trends in app usage and downloads, as well as pricing strategies in the German online pharmacy market.
The data suggests that Redcare is increasing its price investments, while DocMorris is decreasing such measures.
Furthermore, app activity among Swiss users is reportedly declining, indicating that DocMorris is falling behind Redcare.
This analysis is based on regular figures on the performance of online pharmacies, highlighting the competitive landscape in the sector.